Contents

Preface —— V
List of contributing authors —— XV

Part I: **Chemical engineering and medicine**

I. David L. Bogle and John Martin
1 A systems engineering approach to medicine —— 3
1.1 Introduction —— **3**
1.2 Physiological systems and complexity —— **5**
1.3 How complicated can this really be? —— **7**
1.4 An example: the cardiovascular system —— **9**
1.4.1 The arterial wall —— **9**
1.4.2 The blood —— **10**
1.4.3 The catastrophic event —— **10**
1.4.4 Therapeutics —— **11**
1.4.5 The system —— **11**
1.5 The power of purpose —— **12**
1.6 Do we really understand? —— **13**
1.7 What can we do? An expanded role for engineers —— **14**
References —— **16**

Part II: **Modelling physiology**

Yunjie Liao, Nathan A. Davies and I. David L. Bogle
2 Computational modelling in liver system and liver disease —— 21
2.1 The liver – the Body's chemical factory —— **21**
2.2 Liver physiology – fundamentals of hepatic function —— **22**
2.2.1 Anatomy and structure —— **22**
2.2.2 Liver Sinusoid and Hepatic Zonation —— **24**
2.3 Liver disease – the leading cause of death in UK —— **25**
2.3.1 Classifications of liver disease —— **25**
2.3.2 MASLD – the alarming crisis —— **26**
2.4 Glucose & fructose – a "sweet" burden —— **28**
2.5 Systems biology approach–the rising star —— **29**
2.6 Computational modelling of fructose-induced lipid deposition and MASLD —— **30**
2.6.1 Experimental Attempt and Exploration —— **31**
2.6.2 Computational Model Development of Fructose Metabolism —— **34**
2.6.3 Experimental Assessment —— **42**

Bibliografische Informationen
http://d-nb.info/1374601764

digitalisiert durch DEUTSCHE NATIONAL BIBLIOTHEK

2.6.4 Project Conclusions and Future work — **42**
2.7 Chapter conclusion — **45**
References — **45**

Tomasz R. Sosnowski and Arkadiusz K. Kuczaj
3 Inhaled aerosols as carriers of pulmonary medicines and the limitations of *in vitro–in vivo* correlation (IVIVC) methods — 49
Abbreviations — **49**
3.1 Introduction — **50**
3.2 The IVIVC problem for inhaled aerosols — **52**
3.3 Basics of aerosol dynamics in the respiratory system — **53**
3.4 Drug delivery devices for inhalation therapies — **55**
3.5 Aerosol characterization assessment methods — **57**
3.6 Inter-patient variability (anatomy, respiratory physiology) — **63**
3.7 Generic inhalation drug products delivery — **65**
3.8 Perspectives and final remarks — **66**
References — **68**

Daniel Sebastia-Saez, Tao Chen, Benjamin Deacon and Guoping Lian
4 Modelling drug permeation across the skin: a chemical engineering perspective — 73
Abbreviations — **75**
4.1 Introduction — **75**
4.2 Skin physiology — **77**
4.3 Mechanistic mathematical models for drug permeation across the skin — **78**
4.3.1 Compartmental models — **79**
4.3.2 Spatial diffusion-based models — **81**
4.4 Beyond the basics: chemical transfer facilitated by external forces — **87**
4.5 Case studies — **88**
4.5.1 Integrated evaporation and skin permeation for *in-vitro* permeation — **89**
4.5.2 Dermal permeation and delivery through the follicular pathway — **94**
4.6 Perspectives and concluding remarks — **98**
References — **99**

Maryam Zarghami Dehaghani, Thomas Fabiani and Maria Grazia De Angelis
5 Chemical engineering contribution to hemodialysis innovation: achieving the wearable artificial kidneys with nanomaterial-based dialysate regeneration — 103
5.1 Introduction — **103**
5.1.1 Kidney functionality and uremic toxins — **103**
5.1.2 Chronic kidney disease and hemodialysis design — **105**

5.2 Basic equipment of conventional hemodialysis — **105**
5.3 Developing dialysate regeneration techniques for the wearable artificial kidney — **109**
5.3.1 Regeneration of spent dialysate: technologies for uremic toxins elimination — **110**
5.3.2 Adsorption materials for UT removal — **112**
5.4 Conclusions — **118**
References — **119**

Part III: **Disease and treatment**

Davide Manca
6 Precision medicine in hypothyroidism: an engineering approach to individualized levothyroxine dosing — 127
6.1 Introduction — **127**
6.2 The thyroid gland — **128**
6.2.1 Microstructure — **129**
6.2.2 Synthesis of thyroid hormones — **129**
6.2.3 Regulation of thyroid hormone secretion — **131**
6.2.4 Pathologies of the HPT axis — **132**
6.3 State of the art in hypothyroidism treatment — **135**
6.3.1 Treatment of hypothyroidism — **137**
6.4 A compartmental model of the HPT axis — **139**
6.4.1 BRAIN submodel — **140**
6.4.2 TH submodel — **141**
6.4.3 Input submodel — **144**
6.5 A model-based approach to the prediction of the optimal levothyroxine dose — **145**
6.5.1 Real patient case study — **153**
6.5.2 Robustness of the algorithm — **156**
6.6 Model validation — **156**
6.6.1 Validation of clinical data from real patients — **156**
6.7 Conclusions — **162**
References — **163**

Carlota Guati, Lucía Gomez-Coma, Marcos Fallanza and Inmaculada Ortiz
7 Glucose sensors in medicine: overview — 167
7.1 Glucose sensors in medicine: overview — **167**
7.1.1 Beyond diabetes: other diseases and applications — **167**
7.1.2 Diabetes mellitus: a pressing healthcare challenge — **169**
7.2 Glucose recognition methods — **170**

7.2.1 Electrochemical discrete and continuous measurements — **171**
7.2.2 Catalytic materials: enzymes and metallic structures — **173**
7.3 4th generation of glucose sensors: state of art — **175**
7.3.1 Beyond enzymes: a materials revolution — **175**
7.4 Challenges and considerations — **180**
7.4.1 Social considerations — **180**
7.4.2 Performance considerations — **181**
7.4.3 The future challenges of FGGS — **183**
References — **183**

Álvaro González-Garcinuño, Antonio Tabernero and Eva Martín del Valle
8 Macroscopic transport models for drugs and vehicles in cancer tissues — 185
8.1 Introduction: the importance of modeling drug transport in cancer. Types of models — **185**
8.1.1 Pharmacokinetics (PK)–Pharmacodynamics (PD) models — **186**
8.1.2 Microscopic models — **187**
8.1.3 Macroscopic models — **188**
8.2 Physiology of cancer and necrotic tissues — **188**
8.2.1 Pressure gradient — **189**
8.2.2 Tumor vasculature. Blood irrigation — **189**
8.2.3 Lymphatic drainage — **189**
8.3 Classical transport equations and phenomena — **190**
8.4 Improving models using realistic geometries — **196**
8.5 Conclusions and perspectives — **198**
References — **199**

Nunzio Cancilla, Luigi Gurreri, Michele Ciofalo, Andrea Cipollina, Alessandro Tamburini and Giorgio Micale
9 Mathematical modelling of hollow-fiber haemodialysis modules — 203
9.1 Introduction — **203**
9.1.1 Structure and function of the kidney — **204**
9.1.2 Kidney diseases and malfunction — **206**
9.2 Membrane-based renal replacement treatments (RRT) — **208**
9.2.1 Technological evolution of membrane modules for haemodialysis — **208**
9.2.2 Transport mechanisms of solute removal: haemodialysis, haemofiltration, haemodiafiltration — **210**
9.3 Performance figures and quantities affecting them — **214**
9.4 Small-scale (unit cell) modelling of the haemodialysis process — **215**
9.4.1 Regular lattices: single-fiber models — **215**
9.4.2 Non-ideal phenomena: effects of non-uniform and random fiber distributions — **224**
9.5 Module-scale 3-D porous media models — **226**

9.5.1 Small-scale CFD correlations — **227**
9.5.2 Porous media approach — **227**
9.5.3 Estimation of mass transport resistances — **229**
9.5.4 Computational domain and simulation strategy — **230**
9.5.5 Model validation — **233**
9.5.6 Fluid flow and solute concentration distributions — **234**
9.5.7 Parametric sensitivity assessment — **234**
9.6 Conclusions and outlook — **236**
References — **237**

Krystian Jędrzejczak, Arkadiusz Antonowicz, Krzysztof Wojtas, Wojciech Orciuch, Malenka Bissell and Łukasz Makowski

10 Chemical engineering methods in better understanding of blood hydrodynamics in atherosclerosis disease — 243
10.1 Introduction of physiology of the circulatory system — **244**
10.2 Mathematical modeling — **245**
10.2.1 Mathematical flow formulation — **245**
10.2.2 Rheology and hemolysis models — **246**
10.2.3 Numerical schemes — **247**
10.3 Experimental techniques — **249**
10.3.1 Medical imaging — **249**
10.3.2 Experimental verification techniques — **249**
10.4 Results — **251**
10.5 Conclusions — **255**
References — **256**

Federico Galvanin, Chun Fung Lee and Yuxuan Yang

11 On the development of pharmacokinetic models for the characterisation and diagnosis of von Willebrand disease — 263
11.1 Introduction — **263**
11.2 Clinical diagnosis of von Willebrand disease — **266**
11.3 From fundamental mechanisms to VWD modelling — **267**
11.4 Model-based diagnosis of VWD — **269**
11.4.1 Pharmacokinetic models of VWD — **270**
11.4.2 Identification of haemostatic parameters from DDAVP tests — **274**
11.4.3 Models including exogenous infusion of VWF concentrates — **276**
11.5 Model-based diagnosis of VWD subjects — **277**
11.6 Model-based design of clinical tests — **280**
11.7 Design of single and multiple infusion tests for the treatment of AVWS — **281**
11.7.1 Preliminary parameter estimation from DDAVP and VWF infusion tests data — **281**

11.7.2 Optimal design of Haemate P administration tests including single and multiple infusion —— **284**
11.8 Conclusions —— **287**
References —— **288**

Part IV: **Pharmacokinetics and drug delivery**

Roberto A. Abbiati and Cesar Pichardo
12 An introduction to quantitative systems pharmacology for chemical engineers —— 293
12.1 Introduction to pharma R&D —— **293**
12.2 Quantitative systems pharmacology —— **295**
12.3 QSP application space —— **296**
12.3.1 Disease progression —— **296**
12.3.2 Biomarkers —— **297**
12.3.3 Patient variability and virtual populations —— **297**
12.4 Mathematical characteristics of QSP models —— **298**
12.5 Chemical engineering modelling theory affinities to QSP —— **299**
12.6 Examples of the application of QSP modelling in drug development —— **300**
12.6.1 Development of bispecifics antibodies —— **300**
12.6.2 QSP modelling of T-cell engagers —— **301**
12.6.3 Model-based analysis of neutropenia to explore clinical dosing schedule options —— **307**
12.7 Conclusions —— **309**
References —— **310**

Ewa Dluska and Agnieszka Markowska-Radomska
13 A novel strategy for brain cancer treatment through a multiple emulsion system for simultaneous therapeutics delivery —— 315
13.1 Introduction —— **316**
13.2 The concept of multiple emulsions as a dual drug delivery system for brain tumour treatment —— **319**
13.3 Preparation of multiple emulsion-based delivery system —— **319**
13.4 Drug release study in the biological system with multiple emulsion-based delivery implant and cancer cells —— **321**
13.5 Evaluation of the effectiveness of a multiple emulsion-based delivery system —— **323**
13.6 Drug release predictions from a multiple emulsion-based delivery system: mass transfer modelling —— **323**
13.7 Conclusions —— **328**
References —— **330**

Elnaz Jamili, Amit C. Nathwani and Vivek Dua
14 Model-based dose selection for gene therapy for haemophilia B — 333
14.1 Introduction — **334**
14.1.1 Chemical engineering and haemophilia B — **334**
14.1.2 Haemophilia B — **334**
14.2 Methods — **335**
14.2.1 Clinical data — **335**
14.2.2 Pharmacokinetic modelling — **336**
14.2.3 Pharmacodynamic modelling — **337**
14.2.4 Incorporating the toxicological model — **338**
14.3 Results and discussion — **339**
14.3.1 Parameter estimation — **340**
14.3.2 Initial dose selection — **353**
14.4 Conclusions — **356**
References — **356**

Sonia Sarnelli, Manuel Cardamone, Ernesto Reverchon and Lucia Baldino
15 Lipid-based nanoparticles for nucleic acids delivery — 359
15.1 Historical background of nucleic acids — **359**
15.1.1 The evolution of medicine: from conventional drugs to nucleic acid-based therapies — **360**
15.1.2 Analogies and differences between DNA and RNA — **360**
15.1.3 mRNA-based therapies — **361**
15.2 RNA delivery systems — **363**
15.2.1 Viral vectors — **363**
15.2.2 Non-viral vectors — **363**
15.2.3 Composition of lipid-based nanocarriers for RNA delivery — **366**
15.3 Conventional and innovative methods to produce lipid-based systems — **371**
15.3.1 Conventional techniques — **371**
15.3.2 Innovative techniques — **372**
15.4 Discussion, conclusions and future perspectives — **374**
References — **375**

Index — 381